Maria
Sundvall
Docent, Institute of Biomedicine
Clinical Lecturer, Institute of Biomedicine
Researcher, Institute of Biomedicine
Senior Researcher, Institute of Biomedicine
MD PhD; Specialist Physician in Clinical Oncology
Areas of expertise
clinical oncology
breast and prostate cancer
targeted cancer therapeutics
cancer biology
cell signaling
posttranslational modifications
dna repair pathways
Biography
Maria Sundvall received her MD degree from the University of Turku in 2003, and defended her PhD thesis at the Department of Medical Biochemistry and Genetics, University of Turku, in 2007. From 2011 she worked nearly 4 years as a postdoctoral fellow in the laboratory of Prof. Pier Paolo Pandolfi, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA. After returning to Finland in 2015 she established her own research group at the University of Turku. Dr. Sundvall received a specialist physician degree in clinical oncology in 2018. Since 2018 Dr. Sundvall has worked as a part-time clinical lecturer at the Institute of Biomedicine, a part-time Academy of Finland clinical researcher and a part-time specialist physician in clinical oncology at Turku University Hospital.
Teaching
Dr. Sundvall has several years of experience in teaching medical students as a clinical lecturer and a university teacher in the fields of medical biochemistry, molecular medicine and cancer during the last 15 years.
Research
Dr. Sundvall has 20 years of experience in studying molecular mechanisms of cancer. Currently she is a principal investigator at University of Turku, and her group is focusing on investigating the role fo DNA repair pathways in prostate cancer. Links:
https://www.utu.fi/en/university/faculty-of-medicine/institute-of-biomedicine/research/cancer-research
https://www.utu.fi/en/university/faculty-of-medicine/institute-of-biomedicine/research/cancer-research
Publications
Therapeutic Potential of Targeting the SUMO Pathway in Cancer (2021)
Cancers
(Vertaisarvioitu katsausartikkeli tieteellisessä aikakauslehdessä (A2))
Uusia työkaluja paikallisesti edenneen ja etäpesäkkeisen eturauhassyövän lääkehoitoon (2020)
Duodecim
(Vertaisarvioitu katsausartikkeli tieteellisessä aikakauslehdessä (A2))
Role of Ubiquitin and SUMO in Intracellular Trafficking (2020)
Current Issues in Molecular Biology
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
PARP Inhibitors in Prostate Cancer-the Preclinical Rationale and Current Clinical Development (2019)
Genes
(Vertaisarvioitu katsausartikkeli tieteellisessä aikakauslehdessä (A2))
Role of Ubiquitin and SUMO in Intracellular Trafficking (2019)
(O2 Muu julkaisu )Different responses of colorectal cancer cells to alternative sequences of cetuximab and oxaliplatin (2018)
Scientific Reports
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
SUMOylation regulates nuclear accumulation and signaling activity of the soluble intracellular domain of the ErbB4 receptor tyrosine kinase (2017)
Journal of Biological Chemistry
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
ERBB4 Promoter Polymorphism Is Associated with Poor Distant Disease-Free Survival in High-Risk Early Breast Cancer (2014)
PLoS ONE
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
A metabolic prosurvival role for PML in breast cancer (2012)
Journal of Clinical Investigation
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Protein inhibitor of activated STAT3 (PIAS3) protein promotes SUMOylation and nuclear sequestration of the intracellular domain of ErbB4 protein (2012)
Journal of Biological Chemistry
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))